Merck Cost-Cutting Program Will Help Beat First Quarter Expectations, Company Says
This article was originally published in The Pink Sheet Daily
Merck expects first quarter performance will come in at 62¢ per share, about 11% ahead of analysts' expectations. Despite stronger-than-expected first quarter, Merck is reaffirming full-year guidance.
You may also be interested in...
Normalization of Prevnar demand after the correction of supply problems will play a major role in delivering first quarter earnings per share levels significantly higher than analyst estimates, CFO Martin says. Third quarter results may be down compared to 2004 because of high anticipated R&D spending.
Merck increases reserve for legal defense costs related to Vioxx by $604 mil., bringing the total to $675 mil.; the company has not yet established a reserve to cover potential liability. A hearing to consolidate pretrial motions to a single federal judge is scheduled for Jan. 27.
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.